Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Chiral nanomaterials for tumor therapy: autophagy, apoptosis, and photothermal ablation.
J Nanobiotechnology. 2021 Jul 22;19(1):220. doi: 10.1186/s12951-021-00965-7.
J Nanobiotechnology. 2021.
PMID: 34294083
Free PMC article.
Review.
Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.
Xuhong JC, Qi XW, Zhang Y, Jiang J.
Xuhong JC, et al.
Am J Cancer Res. 2019 Oct 1;9(10):2103-2119. eCollection 2019.
Am J Cancer Res. 2019.
PMID: 31720077
Free PMC article.
Review.
Item in Clipboard
Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
Xuhong J, Qi X, Tang P, Fan L, Chen L, Zhang F, Tan X, Yan W, Zhong L, He C, Liang Y, Ren L, Wang M, Zhang Y, Jiang J.
Xuhong J, et al.
Oncologist. 2020 Dec;25(12):e1909-e1920. doi: 10.1002/onco.13546. Epub 2020 Oct 20.
Oncologist. 2020.
PMID: 33000490
Free PMC article.
Clinical Trial.
Item in Clipboard
Development and validation of a prognostic nomogram for early HER2-positive and lymph node-negative breast cancer.
Shi Q, Wang J, Ai X, Xuhong J, Ma D, Zhang Y, Qi X, Jiang J.
Shi Q, et al. Among authors: xuhong j.
Gland Surg. 2021 Jul;10(7):2255-2265. doi: 10.21037/gs-21-392.
Gland Surg. 2021.
PMID: 34422596
Free PMC article.
Item in Clipboard
Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
Qi X, Shi Q, Xuhong J, Zhang Y, Jiang J.
Qi X, et al. Among authors: xuhong j.
Breast Cancer Res. 2023 Oct 3;25(1):113. doi: 10.1186/s13058-023-01694-5.
Breast Cancer Res. 2023.
PMID: 37789330
Free PMC article.
Review.
Item in Clipboard
Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis.
Shi Q, Xuhong J, Tian H, Qu M, Zhang Y, Jiang J, Qi X.
Shi Q, et al. Among authors: xuhong j.
Biochim Biophys Acta Rev Cancer. 2023 Jan;1878(1):188847. doi: 10.1016/j.bbcan.2022.188847. Epub 2022 Dec 11.
Biochim Biophys Acta Rev Cancer. 2023.
PMID: 36516931
Review.
Item in Clipboard
PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
Shi Q, Xuhong J, Luo T, Ge J, Liu F, Lan Y, Chen Q, Tang P, Fan L, Chen L, Liang Y, Wang M, Hu Y, Zhang Y, Bian X, Qi X, Jiang J.
Shi Q, et al. Among authors: xuhong j.
Br J Cancer. 2023 Jan;128(1):121-129. doi: 10.1038/s41416-022-02021-z. Epub 2022 Nov 2.
Br J Cancer. 2023.
PMID: 36323880
Free PMC article.
Item in Clipboard
Cite
Cite